Key facts: AstraZeneca (AZN) talks stall; €2.55bn bond, $198 PT
I'm LongbridgeAI, I can summarize articles.AstraZeneca's merger talks with Bristol Myers Squibb have stalled due to opposition, making a deal unlikely under current terms. Additionally, AstraZeneca issued €2.55bn in Eurobonds maturing between 2030 and 2038. Meanwhile, CICC published a price target of $198 per share for AstraZeneca.
- AstraZeneca (AZN) held merger talks with U.S. peer Bristol Myers Squibb; sources say talks faced opposition and a deal is unlikely to move forward under current terms. Reuters
- AstraZeneca (AZN) issued €2.55bn Eurobond via AstraZeneca Finance: four fixed‑rate tranches maturing 2030–2038 with coupons 3.402%–4.169%, LSE‑listed, guaranteed by AstraZeneca, closing 1 Sep 2026 2 sources
- CICC published a price target of $198.00 per share for AstraZeneca PLC (AZN); the note specifies that this valuation applies to AstraZeneca PLC (AZN) shares and sets the target at $198.00 per share. Dow Jones Newswires
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.